---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-347211"
form_type: "8-K"
ticker: "BSEM"
cik: "0001658678"
company_name: "BioStem Technologies, Inc."
filed_at: "2026-08-12T21:27:17+00:00"
generated_at: "2026-08-12T21:28:05.574315+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioStem Q2 revenue $7.9M (up 29% QoQ), net loss $9.0M, raises FY26 guide

## Summary
- Q2 2026 net revenue $7.9M vs $6.1M Q1 2026 (+29%) and $11.0M Q2 2025; hospital $6.7M, physician $1.1M.
- GAAP net loss $9.0M ($0.52/share) vs income $10,613 in Q2 2025; adjusted EBITDA loss $4.6M.
- Cash $7.0M at June 30, 2026 (from $13.7M); used $5.5M in ops; closed $2.5M private placement.
- Resolved $5.3M debt via $3.5M cash and $1.0M promissory note; uplisted to Nasdaq Capital Market Aug 7, 2026.
- Raises FY2026 revenue guidance to $26-29M from $25-29M; issued eight new U.S. design patents.

## SEC filing metadata
- accession: 0001193125-26-347211
- form_type: 8-K
- ticker: BSEM
- cik: 0001658678
- company_name: BioStem Technologies, Inc.
- filed_at: 2026-08-12T21:27:17+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658678/000119312526347211/0001193125-26-347211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658678/000119312526347211/bsem-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-347211
- JSON: https://secwatch.observer/filing/0001193125-26-347211.json
- Plain text: https://secwatch.observer/filing/0001193125-26-347211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.